Oncology
02/2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
Oncology
02/2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
Oncology
11/2015

A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity

EORTC-NCI-AACR International Conference
Read More
Oncology
11/2015

Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference
Read More
Oncology
11/2015

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

EORTC-NCI-AACR International Conference
Read More
Oncology
11/2015

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference
Read More
PRESS RELEASES
11/2015

3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA

Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference…
Read More
PRESS RELEASES
09/2015

3-V Biosciences to Present Data at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna

Menlo Park, California, September 17, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from its ongoing Phase 1 clinical…
Read More
PRESS RELEASES
08/2015

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush…
Read More
Oncology
07/2015

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

EBioMedicine
Read More